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Introduction: Stroke is one of the leading causes of mortality and disability. Clinical studies conducted in patients with a recent ischemic stroke 
and treated with policosanol (20 mg/day) + standard aspirin (AS) (125 mg/day) therapy have shown benefits versus placebo + AS to patients 
with recent ischemic stroke. The objective of the present paper is to a preliminary retrospective analysis of the policosanol treatment effects in 
the patients included in ischemic stroke recovery trials.  
Methods: This report analysed the records of all patients included in four ischemic stroke recovery studies. Patients with a modified Rankin 
Scale score (mRSs) 2 to 4 were randomized, within 30 days of onset, to policosanol+AS or placebo+AS, for 6 and 12 months. The primary 
outcome was mRSs reduction. Decreases on low-density lipoprotein-cholesterol (LDL-C), total cholesterol and increases on high-density 
lipoprotein-cholesterol (HDL-C) were secondary outcomes.  
Results: Two hundred and seventy one patients (mean age: 67 years) were included in the analysis. At the six months more policosanol+AS 
(117/136, 86 %) than placebo+AS patients (10/135, 7.3 %) achieved mRSs goals. In correspondence, at the 12 months of the study more 
policosanol+AS (50/59, 84.7 %) than placebo+AS patients (5/59, 8.5 %) achieved mRSs goals. Treatment with policosanol+AS significantly 
decreased mean mRSs from the first interim check-up. The treatment effect did not wear off, even improved, after 6 and 12 months therapy when 
the net decrease versus placebo+AS was 56 % and 70.8 %, respectively. In addition, policosanol+AS reduced significantly LDL-C (21.6 %) and 
total cholesterol (12.5 %), and increased HDL-C (6.3 %). Treatments were safe and well tolerated. Eight patients reported serious adverse 
events (6 placebo+AS, 2 policosanol+AS) and other 13 patients (8 placebo+AS, 5 policosanol+AS) reported moderate or mild adverse events. 
Conclusions: The preliminary retrospective analysis of the effects of policosanol+AS on ischemic stroke patients indicate that this treatment for 
6 and 12 months proved to be more effective than the placebo+AS treatment in the functional recovery of these patients.   
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I. INTRODUCTION  
schemic stroke is the second leading cause of death 
worldwide as well as the leading cause of long-term 
disability.
1,2
 About half of stroke survivors remain with 
physical or cognitive impairment that severely affect their 
physical and social functions. Also, stroke implies a high cost 
to patients, families and health systems.
3  
Stroke occurs when blood flow to the brain is interrupted, 
without oxygen-rich blood, brain cells die. Most strokes (87 % 
of cases) are classified as ischemic (a clot or a mass blocks a 
blood vessel, cutting off blood flow to a part of the brain).
1
  
It is important to identify risk factors and sources of stroke 
in order to take steps towards preventing stroke. Primary 
prevention addresses all measures for avoiding a stroke or 
transient ischemic attack. Secondary prevention addresses all 
measures for avoiding recurrences after a first transient 
ischemic attack or stroke manifestation, which is becoming 
more frequent in an increasingly ageing population.
4-6
 
Control of modifiable ischemic stroke risk factors, such as 
hypertension, diabetes, dyslipidemia, cigarette smoking and 
obesity are key measures to prevent recurrent strokes.
6 
 
Aspirin (AS) remains the gold standard of antiplatelet 
therapy for stroke recovery and prevention, and several studies 
and meta-analyses support the merits of antiplatelet drugs in 
stroke prevention by lowering platelet function, which reduces 
thrombotic complications of atherosclerosis.
7-10  
Reduction of low-density lipoprotein-cholesterol (LDL-C) 
levels has been shown to be relevant not only for stroke 
prevention,
11,12 
but also for improving functional outcomes 
after stroke, a key matter for reducing the disability after 
stroke.
13-15 
Policosanol, a mixture of 8 high molecular weight 
sugarcane wax alcohols, has shown protective effects in 
experimental brain ischemia,
16-18 
and clinical studies have 
found coherent results.
19-25  
In light of these facts, a preliminary retrospective analysis 
was undertaken to verify whether policosanol added to AS 
within 30 days of stroke onset, is better than placebo + AS for 
the six and 12 months recovery of ischemic stroke patients 
included. 
II. MATERIALS AND METHODS 
The present analysis includes the data of all patients 
included in ischemic stroke recovery studies.   
Studies Design 
Patients who suffered recent ischemic stroke (≤ 30 days 
before recruitment) and gave their informed written consent 
enrolled at external visits of the Institute of Neurology and 
Neurosurgery (Havana, Cuba). The independent Ethics 
Committee approved the studies protocols and the studies 
were registered in the Cuban Public Registry of Clinical 
Studies.  
I 
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All participants underwent clinical history and full clinical 
examination. All the patients included in the study were 
indicated and received rehabilitation in their Polyclinics of 
residence and were recommended to follow a healthy lifestyle, 
with control of blood pressure, smoking cessation, low fat and 
calorie diet, systematic physical activity and eliminate alcohol 
consumption. 
Eligible patients were randomized to policosanol + AS or 
placebo + AS for 6 and 12 months and attended to control 
visits at 3; 6, 9 and 12 months on treatment. Patients 
underwent general examination and neurological assessment 
at each visit, laboratory analyses at baseline and at 6 and 12 
months on therapy, meanwhile we controlled treatment 
compliance and adverse events at each visit post 
randomization.  
Studies Patients 
Enrolled patients were ambulatory men and women over 
40 years of age
 
who had ischemic stroke (diagnosed
 
by a 
neurologist) within the 30 days prior to enrolment.  
The studies protocol defined stroke as the occurrence of 
focal clinical signs of central nervous system dysfunction
 
of 
vascular origin that lasted for at least 24 hours. Ischemic 
stroke confirmed through clinical assessment and 
computerized axial tomography performed within the 
following 48 hours after stroke onset in patients
 
were eligible 
for randomization if they had a modified Rankin Scale score 
(mRSs)
25
 of 2, 3 or 4.
 
The exclusion criteria included 
suspected or confirmed haemorrhagic stroke, atrial fibrillation, 
other cardiac sources
 
of embolism, subarachnoid haemorrhage, 
diastolic hypertension  110 mm Hg, cardiac valve diseases, 
history of myocarial infarction, instable angina or 
revacularisation surgery within the six months prior to the trial 
and previous consumption of policosanol or other lipid-
lowering and antiplatelet drugs. 
Treatment 
Patients consumed policosanol+AS or placebo + AS once 
daily with the breakfast for 6 and 12 months. Keeping in mind 
that randomised controlled trials support the use of daily doses 
of AS (75–150 mg) for the prevention of vascular events in 
high-risk patients we used 125 mg/day.
7-10 
Good treatment compliance, assessed through counts of 
remainder tablets and patient’s interviews, was to consume at 
least 85 % of the scheduled tablets per period evaluated. 
Antiplatelet (different to policosanol and AS) or lipid-
lowering drugs were not permit to use during the study. 
No patients included in the study received rechannel 
treatment neither with rTPa nor with mechanical 
thrombectomy. 
Studies Outcomes 
Clinical response was defined in terms of stroke functional 
scale (mRSs), which measure patient disability.
26,27  
The primary outcome of this study was functional outcome 
measured by the mRSs, which assesses the outcome with 
scores that range from 0 to 6 (0 no symptoms; 1 no relevant 
disability despite symptoms, able to conduct all usual 
activities; 2 slight disability, unable to carry out all previous 
activities but able to conduct self-assistance; 3 moderate 
disability requiring some help, but able to walk without 
assistance; 4 moderate severe disability, unable to walk 
without assistance, and unable to attend body needs without 
assistance; 5 serious disability; bedridden, incontinent, and 
requiring constant care and attention; and 6 death).
27 
We assumed to obtain a higher rate of cases with a 
favourable stroke outcome (mRSs ≤1) than in the placebo/AS 
group. In addition, reduction of mean mRSs with 
policosanol/AS should be greater than with placebo/AS. To 
obtain mRSs ≤ 1 are considered as favourable post stroke 
outcomes.
14,15 
The modified Rankin neurological scale (mRSs) was 
always applied and evaluated by the principal investigator. All 
the patients included in the study had mRSs before the 
ischemic stroke of 0. 
Decreases on LDL-C, total cholesterol and increases on 
HDL-C levels were secondary outcomes. 
Laboratory Analyses 
Venous blood samples were taken following a fasting of 
12 hours. Plasma was separated from red blood cells
 
by 
centrifugation at 4°C and 2000 x g for 10 min, and aliquots 
were immediately taken. Lab analyses were performed within 
the next 8 hours after blood drawing.  
Lipid Profile and Blood Safety Indicators  
Serum lipids levels as well as blood biochemistry (alanine 
amino transferase-ALT, aspartate amino transferase-AST, 
glucose and creatinine) indicators were determined using 
reagent kits (Roche, Basel, Switzerland) in a Hitachi 719 
autoanalyzer (Tokyo, Japan) of the Clinical Laboratory.  
Safety and Tolerability Assessment 
Safety and tolerability indicators included laboratory and 
physical examination data, and adverse events (AE) reports. 
Study protocol defined an AE as any undesirable experience, 
absent at hospital discharge or worsened thereafter, happening 
in a patient, independently if it could be or not related with the 
therapy. AE were classified as mild, moderate or serious 
according to their intensity. Mild AE should not require 
stopping of study medications or specific treatment of the AE, 
moderate AE should require the withdrawal of study 
medications and/or treatment of the AE, while serious AE 
should lead to patient hospitalization and/or to death. 
 
Statistical Analysis 
The study was designed to have a statistical power of 80 % 
 
to detect a reduction of 30 % in the frequency of 
policosanol+AS cases with a favourable outcome as compared 
to the placebo+AS group, with a two-sided
 
significance level 
of p<0.05. We analyzed the data on an intention-to-treat
 
basis, 
including those of all patients who underwent randomization. 
Continuous values were compared with the t test for paired 
(within group comparisons) and independent (between group 
comparisons) samples, and the Bonferroni´s test was used to 
adjust significances from repeat comparisons.
28
 Categorical 
data were compared with the Chi square test. All p values 
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were two-sided.  
III. RESULTS 
Population characteristics 
Two hundred and seventy one patients enrolled (mean age: 
67 years) (135 men, 136 women) were eligible for 
randomization. One hundred and fifty three patients (77 
policosanol and 76 placebo) were included in the six months 
studies and one hundred eighteen patients (59 policosanol and 
59 placebo) were included in the long-term studies (12 
months).  
Twenty nine patients (16 placebo+AS, 13 policosanol+AS) 
discontinued prematurely the trials, because of serious adverse 
events (6 placebo+AS, 2 policosanol+AS), travels abroad (3 
placebo+AS group, 5 policosanol+AS), protocols violations (2 
placebo+AS, 2 policosanol+AS),  unwillingness to follow-up 
(5 placebo+AS, 3 policosanol+AS) and change of localization 
(1 policosanol+AS). 
Baseline characteristics were well balanced in the two 
groups (Table I). The most frequent (≥ 20 %) risk factors at 
baseline were hypertension (93.4 %), over weight + obesity 
(62.4 %), smoking (39.5 %), hypercholesterolemia (18.8 %) 
and diabetes (16.6 %). Concomitant therapy was also well 
matched in both groups, the most frequent being the 
angiotensin converting enzyme inhibitors (ACEI) (74.9 %).  
Effects on Stroke Functional Outcomes  
Table II shows the distribution of patients into different 
mRSs values at baseline, and after 3, 6, 9 and 12 months on 
treatment. Baseline values were similar in both groups. In all 
comparisons, more patients treated with policosanol+AS than 
with placebo+AS achieved mRSs ≤1.  
At the six months more policosanol+AS (117/136, 86.0 %) 
than placebo+AS patients (10/135, 7.3 %) achieved mRSs 
goals (p0.001). At the 12 months of the study more 
policosanol+AS (50/59, 84.7 %) than placebo+AS patients 
(5/59, 8.5 %) achieved mRSs goals (p0.001). 
 








Age (years) (XDE) 67  11 67  10 67  11 
Body mass index (kg/m2)(XDE) 26.3  2.5 26.6  2.9 26.4  2.7 
mRSs (XDE) 2.9  0.5 2.7  0.5 2.8  0.5 
 n % n % n % 
Sex:  Women 66 48.5 70 51.9 136 50.2 
Men 70 51.5 65 48.1 135 49.8 
Personal history       
Hypertension 126 92.5 127 94.1 253 93.4 
Overweight & obesity 89 65.4 80 59.3 169 62.4 
Smoking 53 39.0 54 40.0 107 39.5 
Hypercholesterolemia 23 16.9 28 20.7 51 18.8 
Diabetes mellitus 23 16.9 22 16.3 45 16.6 
Concomitant therapy    
At least 1 concomitant therapy consumieron MC 120 88.2 121 89.6 241 88.9 
ACEI 101 74.3 102 75.6 203 74.9 
Diuretics 24 17.6 27 20.0 51 18.8 
Oral hypoglycaemic drugs 13 9.6 14 10.4 27 10.0 
X mean, SD standard deviation Poli policosanol, AS aspirin, mRSs Modified Ranking Scale score,  
ACEI angiotensing converting enzyme inhibitors 
All comparisons were not significant 
 
TABLE II. Effects on the neurological recovery assessed through the functional stroke scale  (Modified Rankin Scale score-mRSs) (XSD) 
 Baseline 3 months  6 months 9 months 12 months 
Placebo+AS 2.7  0.5 2.5  0.5 2.5  0.7 2.4  0.7 2.4  0.6* 
Poli+AS 2.8  0.5 1.8  0.7** 1.1  0.6*** 0.9  0.4*** 0.7  0.5*** 
(X  SD) mean  standard deviation, Poli policosanol, AS aspirin 
*p<0.00125, ***p<0.001, ***p<0.0001, Comparison vs baseline (t test for paired samples, Bonferroni adjustment) 
p<0.01, p<0.001, p<0.0001 Comparison vs placebo/AS (t test for independent samples) 
 
Table III lists the effects on functional stroke scale. 
Treatment with policosanol+AS significantly decreased mean 
mRSs from the first interim check-up (p0.0001 vs 
placebo+AS). The treatment effect did not wear off, even 
improved, after 6 and 12 months therapy (p<0.0001 versus 
placebo+AS) when the net decrease versus placebo+AS was 
56 % and 70.8 %, respectively.  
Effects on Lipid Profile 
All lipid variables were similar at randomization. No 
significant changes occurred in the placebo+AS group. 
Policosanol+AS decreased persistently and significantly LDL-
C, final reduction was 21.6 %, and the same happened with 
total cholesterol, final decrease was 12.5 % . In turn, the 
treatment increased HDL-C by 6.3 % (Table IV). 
Policosanol+AS failed to modify triglycerides. 
Safety and Tolerability  
According to the effects on physical and blood safety 
indicators, treatments were safe and well tolerated (data not 
shown for simplicity). Systolic and diastolic pressure 
significantly decreased in the group treated with 
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policosanol/AS as compared to placebo/AS throughout the 
study, but individual values were within normal limits. The 
treatment did not modify any other physical or blood safety 
indicator (alanine amino transferase-ALT, aspartate amino 
transferase-AST, glucose and creatinine) versus placebo/AS.  
Eight patients reported serious adverse events (6 
placebo+AS, 2 policosanol+AS). In addition, other 13 patients 
(8 placebo+AS, 5 policosanol+AS) they reported moderate or 
mild adverse events (Table V). 
 
TABLE III. Distribution of cases in accordance to the Modified Ranking Scale score (mRSs) 
mRSs values 













 n n n n n n 
0 0 0 11+ 0 10+ 0 
1 0 0 106++ 10 40++ 5 
0-1 0 0 117++ 10 50++ 5 
2-3 129 133 17++ 121 0++ 45 
4 7 2 0 1 0 0 
Data presented as n (number of cases), Poli policosanol, AS aspirin 
+p < 0.01, ++p < 0.001, Comparisons versus placebo/AS (χ2 test) 
 
TABLE IV. Effects on lipid profile (XSD) 
Treatment Baseline 6 months 12 months 
 LDL-C (mmol/L) 
Placebo+AS 3.47   1.01 3.60   0.98 3.82  1.15 
Policosanol+AS 3.56   0.94 2.78   1.05**++ 2.79  0.81***++ 
 Total cholesterol (mmol/L) 
Placebo+AS 5.75   1.25 5.80   1.12 5.73  1.16 
Policosanol+AS 5.78   1.12 5.40   1.15**++ 5.06  0.96***+ 
 HDL-C (mmol/L) 
Placebo+AS 1.42   0.38 1.41   0.34 1.38  0.35 
Policosanol+AS 1.44   0.37 1.50   0.36* 1.53  0.41** 
 Triglycerides (mmol/L) 
Placebo+AS 1.78   0.94 1.81   0.89 1.83  0.59 
Policosanol+AS 1.76   0.80 1.74   0.98 1.70  0.97 
X mean, SD standard deviation, AS aspirin 
*p < 0.05, **p < 0.01, ***p < 0.001 Comparison vs baseline (t test for paired samples) 
p < 0.05, p < 0.01 Comparison vs placebo/AS (t test for independent samples)  
 
TABLE V. Serious adverse events reported during the studies 
Adverse events (AE) Placebo (n = 135) Policosanol (n=136) 
Serious adverse events (SAE) n % n % 
Recurrent stroke 3 2.2 2 1.5 
Intestinal occlusion-surgery 1 0.7 0 0.0 
Heart attack 1 0.7 0 0.0 
Respiratory failure 1 0.7 0 0.0 
Total of patients who reported SAE 6 4.4 2 1.5 
Moderate or mild AE     
Insomnia 1 0.7 4 2.9 
Gastric discomfort 4 3.0 0 0.0 
Chest pain 1 0.7 0 0.0 
Behavioural troubles 1 0.7 0 0.0 
Asthenia 1 0.7 0 0.0 
Fever episodes 0 0.0 1 0.7 
Total of patients who reported moderate o mild AE 8 5.9 5 3.7 
n number of patients,  no significant (χ2 test) 
 
IV. DISCUSSION 
Study patients were randomized within 30 days of the 
onset of the ischemic stroke, so that the effects of 
policosanol/AS cannot be interpreted as effects on the acute 
stroke, but on the further recovery step. Following the 
recommendations for ischemic stroke management, all 
patients received AS early on their admission in stroke unit 
and followed on the thereafter.
7-10 
Our study group was 
restricted to have 2 to 4 mRSs values for lowering the 
influence of variable stroke severity on the results. Study 
patients had not been received policosanol before being 
randomized, so that they were technically virgin to study 
treatment. 
The strength of the study includes that it was randomized, 
double-blinded and placebo-controlled, with all patients 
receiving AS, first-line therapy recommended after ischemic 
stroke. Since both groups were homogeneous at baseline the 
effects here found can be attributable to policosanol+AS 
therapy. In particular, the mean mRSs values were comparable 
in the two groups. Also, the fact that treatment compliance 
was very good (≥ 85 %) and comparable in both groups 
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supports the validity of the present results.  
Baseline characteristics of study patients match well with 
stroke epidemiological data. The mean age of patients, and the 
high frequency of concomitant morbidities were consistent 
with common stroke risk factors. In addition to AS, consumed 
by all patients, the most frequent concomitant drugs were 
ACEI, but such consumption, coherent with the prevalence of 
hypertension, was also similar in the two groups, so that we 
discard the potential influence of concomitant therapy to the 
present results.  
We assessed the effects on stroke outcome by measuring 
the functional status and degree of functional dependence of 
the patients with the mRSs, scales used widely to assess post-
stroke functional impairment. In particular, mRSs is the 




The present results confirms that the addition of 
policosanol to conventional AS therapy after hospital 
discharge should help the neurological recovery post-ischemic 
stroke. This concept is supported by the proportion of 
policosanol+AS patiens who acchieved a good stroke outcome 
(mRSs≤1) at study completion and the mean reduction (56 % 
and 70.8 % after 6 and 12 months therapy, respectively) of 
mRSs, the primary study outcome, as compared to 
placebo+AS. These results are consistent with the efficacy of 
policosanol+AS demonstrated in previous randomized, 
double-blind controlled studies in which the control group 
received placebo+AS and the net decrease of the mean mRSs 




In addition, policosanol+AS reduced significantly LDL-C 
(31.2 %) and total cholesterol (12 %), and increased HDL-C 
(5.7 %), the lipid-modifying effects here seen are coherent 
with previous data in post-stroke patients,
19-26 
and with the 
general lipid-lowering profile of policosanol.
33-39 
The mechanism(s) whereby policosanol may help to 
improve stroke recovery are beyond the objective of this 
study. Nevertheless, antiplatelet effects of policosanol
40-42 
should be responsible, at least partly, of the benefits of 
policosanol/AS therapy on stroke outcomes
 
over the 
conventional AS therapy. In such regard, a previous 6 months 
clinical study conducted in patients who had suffered non-
cardioembolic ischemic stroke demonstrated that the 
antiplatelet efficacy of policosanol+AS was better than that of 
placebo+AS.
19 
A recent study demonstrated that it inhibits 
cyclooxygenase 1 (COX-1) activity in vitro, which makes 
rationale that it may inhibit platelet aggregation.
43
  
Lipid lowering drugs lowers the stroke risk.
11,21
 Greater 
reductions in stroke risk are associated with higher LDL-C 
decreases.
11 
In a large meta-analysis that included data of 
113000 patients, statin therapy at stroke onset was associated 
with improved outcome.
44  
In this sense also beneficial effects of policosanol on 
serum lipids (LDL-C and TC decrease, HDL-C increase), may 
contribute to the benefits of policosanol+AS on stroke 
outcomes since LDL-C reduction and HDL-C increase are 
linked to stroke recovery and prevention.
11,45
  
The pretreatment with statins, hypercholesterolemia or 
both in ischaemic stroke patients could have neuro-protective 
effects with reduced neurological deficits at presentation, 
lower early death and dependency rate, thus increasing the 
chances for good outcome.
46
 
Moreover, Policosanol (20 mg/day) and atorvastatin (20 
mg/day), administered for 12 weeks within the next 30 days 
after stroke onset, were similarly effective for improving the 




The cholesterol-lowering activity of policosanol involves 
the inhibition of cholesterol synthesis by regulating HMG-
CoA reductase through activation of AMP-kinase,
47,48 
the 
main regulatory kinase for HMG-CoA reductase. Policosanol 
treatment of hepatoma cells increased AMP-kinase 
phosphorylation, providing a clue by which it might down-
regulate HMG-CoA reductase activity and decrease 
cholesterol synthesis without directly inhibiting the enzyme, 
since AMP-kinase.
47 
Further studies demonstrated that 
metabolic transformation of very long chain alcohols to fatty 
acids is needed for the suppression of cholesterol synthesis, 
presumably by increasing cellular AMP levels.
48 
In turn, the 
mechanism(s) responsible of HDL-C elevation by policosanol 
have not been demonstrated. Recent studies have proven that 
policosanol enhances HDL functionality improving anti-






In agreement with previous studies, policosanol+AS was 
safe and well tolerated. The decrease of systolic and diastolic 
blood pressure seen in policosanol+AS group is consistent 
with some previous data,
19-26,34
 indicating an additional 
lowering pressure effect of policosanol. Such additive effects 
on arterial pressure must be in relation with pleiotropic effects 
of policosanol, mainly those supporting beneficial effects on 
endothelial function. 
Finally, we must highlight the favorable results obtained in 
neurological recovery and the recurrence of events in a follow-
up study that evaluated the benefits of policosanol 
administered from hospital discharge up to 5 years later in 55 
patients of both sexes with an accident ischemic stroke that 
had previously undergone transient ischemic attacks. The 
neurological score improved significantly and progressively 
up to the first year after the stroke, and persisted thereafter up 
to the 5 years post-stroke. No patient died during the trial. 
Fifty patients (90.9 %) did not experience a new vascular 
event, 1/55 (1.8 %) suffered a new stroke and 4 (7.3 %) 
experienced a new transient ischemic attacks and no other 




The preliminary retrospective analysis of the effects of 
policosanol on ischemic stroke patients indicate that the 
treatment for 6 and 12 months with policosanol+aspirin 
proved to be more effective than the placebo+aspirin treatment 
in the functional recovery of these patients.   
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